Article Contents ::
Details About Generic Salt :: Vincristine
Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
| 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS |
| VINCRISTINE |
| VINCA ALKALOID | ANTI-NEOPLASTIC |
| PK: D: Extensive M: Hepatic E: feces via bile & urine |
|
Indications & Dose: EWING’S SARCOMA IV Adult 1.4-1.5mg/m2 q7days, max 2mg/m2/wk Child <10 kg: 50µg/kg/wk, >10 kg: 1.4-2mg/m2 q7days, max 2mg/m2/wk | HODGKIN’S/NON-HODGKIN’S LYMPHOMAS IV Adult 1.4-1.5mg/m2 q7days, max 2mg/m2/wk Child <10 kg: 50µg/kg/wk, >10 kg: 1.4-2mg/m2 q7days, max 2mg/m2/wk | IDIOPATHIC THROMBOCYTOPENIC PURPURA IV Adult 1.4-1.5mg/m2 q7days, max 2mg/m2/wk Child <10 kg: 50µg/kg/wk, >10 kg: 1.4-2mg/m2 q7days, max 2mg/m2/wk | LEUKEMIA IV Adult 1.4-1.5mg/m2 q7days, max 2mg/m2/wk Child <10 kg: 50µg/kg/wk, >10 kg: 1.4-2mg/m2 q7days, max 2mg/m2/wk | MEDULLOBLASTOMA IV Adult 1.4-1.5mg/m2 q7days, max 2mg/m2/wk Child <10 kg: 50µg/kg/wk, >10 kg: 1.4-2mg/m2 q7days, max 2mg/m2/wk | MULTIPLE MYELOMA IV Adult 1.4-1.5mg/m2 q7days, max 2mg/m2/wk Child <10 kg: 50µg/kg/wk, >10 kg: 1.4-2mg/m2 q7days, max 2mg/m2/wk | NEUROBLASTOMA IV Adult 1.4-1.5mg/m2 q7days, max 2mg/m2/wk Child <10 kg: 50µg/kg/wk, >10 kg: 1.4-2mg/m2 q7days, max 2mg/m2/wk | RETINOBLASTOMA IV Adult 1.4-1.5mg/m2 q7days, max 2mg/m2/wk Child <10 kg: 50µg/kg/wk, >10 kg: 1.4-2mg/m2 q7days, max 2mg/m2/wk | RHABDOMYOSARCOMA IV Adult 1.4-1.5mg/m2 q7days, max 2mg/m2/wk Child <10 kg: 50µg/kg/wk, >10 kg: 1.4-2mg/m2 q7days, max 2mg/m2/wk | TUMOURS OF BREAST,LUNG,HEAD,NECK & SOFT-TISSUE SARCOMA IV Adult 1.4-1.5mg/m2 q7days, max 2mg/m2/wk Child <10 kg: 50µg/kg/wk, >10 kg: 1.4-2mg/m2 q7days, max 2mg/m2/wk | WILMS’ TUMOR IV Adult 1.4-1.5mg/m2 q7days, max 2mg/m2/wk Child <10 kg: 50µg/kg/wk, >10 kg: 1.4-2mg/m2 q7days, max 2mg/m2/wk |
| Contra: Patients with demyelinating form of charcot-marie-tooth syndrome, hypersensitivity
Precautions: Hepatic impairment, patients receiving concurrent therapy, pulmonary dysfunction, patients with preexisting neuromuscular disease, elderly ADR: Serious: veno-occlusive liver disease, MI, myocardial ischemia, acute uric acid nephropathy, hemolytic uremic syndrome, bronchospasm, anaphylaxis, hypotension, myalgia, peripheral neuropathy, paralysis, cortical blindness, deafness, neurotoxicity, seizure, sensory loss, Others: ataxia, dizziness, fever, headache, neuropathic pain, vertigo, muscle wasting, motor difficulties, back pain, bone pain, deep tendon reflex loss, difficulty walking, gait changes DDI: Serious Digoxin absorption decreases, Zidovudine causes serious myelotoxicity, Vaccines (Live) efficacy diminishes, Itraconazole/Isoniazid increases drug toxicity, MAOIs increases orthostatic hypotension, Warfarin level increases, Nifedipine reduces drug clearance, Phenytoin/Carbamazepine reduces drug efficacy Diet: Monitor: Serum electrolytes, LFTs, neurologic examination, CBC, uric acid |
